Home > Conferences & symposia > NRS webinar > NRS Webinar-Innovative approaches in lung cancer

NRS Webinar-Innovative approaches in lung cancer

NRS webinar-"Innovative Approaches in Lung Cancer" 29 August 12:30-13:30. 

Invited speakers


Dr. Matthew Oser

“Identification of Epigenetic Drivers of Small Cell Lung Cancer LineagePlasticity Using CRISPR/Cas9 Somatic Gene Editing In Vivo”


Dr. MariekeFransen

“Translational research of immunotherapy treated NSCLC, focus on tumor-draining lymph nodes”


Dr. Matthew G. Oser MD, PhD, is a Physician-Scientist in the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School, and the Principal Investigator of a research laboratory within the Division of Molecular and Cellular Oncology at the Dana-Farber Cancer Institute. Dr. Oser obtained a Bachelor of Arts from Oberlin College, and a Doctor of Medicine and Doctor of Philosophy from Albert Einstein College of Medicine. He completed his residency in internal medicine at Brigham and Women’s Hospital, and was a Medical Oncology Fellow in the Dana-Farber/Partners Cancer Care program. In2019, following completion of a post doctoral fellowship in the lab of William G. Kaelin Jr., MD at Dana-Farber Cancer Institute and Harvard Medical School, he began a tenure-track independent investigator position in the Division of Molecular and Cellular Oncology where he heads an independent research laboratory, and a clinical position within the Lowe Center for Thoracic Oncology.

His research laboratory focuses on understanding small cell lung cancer (SCLC) tumorigenesis and identification of new therapeutic strategies for patients with SCLC and other lung neuroendocrine cancers. His specific interests include: 1. Understanding how epigenetic modifying genes regulate the neuroendocrine cell state and lineage plasticity of SCLC; 2. Discovery of new approaches to target the unique neuroendocrine identity of SCLC; 3. Understanding how specific genetic mutations found in SCLC impact tumor development; and 4. Uncovering how these recurrent genetic mutations can be leveraged to develop new selective targeted therapies.

Dr. Oser has been the recipient of a K08 grant and a R37 grant from the NCI, a Lung Cancer Research Foundation Career Development Award, and a Damon Runyon Clinical Investigator Award.

Dr. Marieke Fransen is a Principal Investigator at the department of Pulmonary Medicine at Amsterdam UMC. She obtained her PhD at Leiden University Medical Center (LUMC), CJM Melief as Promotor, on the topic of local immunotherapy of cancer. She worked as a postdoc at LUMC for 4 years, after which she became project leader on her own KWF project, as well as a Roche Postdoc Fellowship. In 2020 she moved to Amsterdam UMC, where she joined the department of Pulmonary Diseases, and the Lung cancer PRG (Patient Research Group, a multidisciplinary group of clinicians and scientist involvement in lung cancer care and research), and establishd her own group in translational research of immunotherapy of NSCLC patients.